NIKKEI 225
28,804.85 +96.25 (+0.34%) HANG SENG
26,126.93 +109.43 (+0.42%) CRUDE OIL
84.05 +0.29 (+0.35%) GOLD FUTURES
1,794.10 -2.20 (-0.12%) DOW
35,677.02 +73.92 (+0.21%) BTC-GBP
44,205.22 -498.41 (-1.11%)
Genmab A/S (GNMSF)
| Previous close | 468.42 |
| Open | 470.42 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 460.58 - 475.42 |
| 52-week range | 299.08 - 500.92 |
| Volume | 104 |
| Avg. volume | 550 |
| Market cap | 31.053B |
| Beta (5Y monthly) | 0.62 |
| PE ratio (TTM) | 79.89 |
| EPS (TTM) | 5.95 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 481.51 |
- Globe Newswire
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021
Company Announcement Net sales of DARZALEX® in the third quarter of 2021 totaled USD 1,580 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. Copenhagen, Denmark; October 19, 2021 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous (SC) formulation (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by Johnson & Johnson were U
- Globe Newswire
Genmab Announces that Janssen has Received Positive CHMP Opinion for RYBREVANT® (amivantamab) for Patients with Advanced Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations, After Failure of Platinum-based Therapy
Media ReleaseCopenhagen, Denmark, October 15, 2021 Janssen-Cilag International NV (Janssen) received a positive CHMP opinion recommending conditional marketing authorization of amivantamab in Europe for the treatment of adult patients with advanced non-small cell lung cancer with activating epidermal growth factor receptor exon 20 insertion mutations, after failure of platinum-based therapyRepresents First CHMP opinion for a DuoBody® product candidate Genmab A/S (Nasdaq: GMAB) announced today th
- Zacks
Seagen's (SGEN) Cancer Portfolio Strong, Stiff Rivalry a Worry
Seagen (SGEN) focuses on improving sales of its marketed drugs that are approved for different types of cancer indications. Stiff competition in the target market remains a woe.
